Page last updated: 2024-08-23

etoposide and belinostat

etoposide has been researched along with belinostat in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Agama, K; Bates, SE; Giaccone, G; Komlodi-Pasztor, E; Luchenko, VL; Murphy, RF; Pommier, Y; Salcido, CD; Varticovski, L; Zhang, Y1
Balasubramaniam, S; Bates, SE; Bryla, C; Ehrlich, S; Figg, WD; Goey, AK; Lee, MJ; Peer, CJ; Piekarz, R; Sissung, TM; Steinberg, SM; Tomita, Y; Trepel, JB1
Balasubramaniam, S; Bates, SE; Bonner, WM; Bryla, C; Figg, WD; Fojo, T; Giaccone, G; Lee, MJ; Peer, CJ; Piekarz, RL; Rajan, A; Redon, CE; Tomita, Y; Trepel, JB1

Trials

2 trial(s) available for etoposide and belinostat

ArticleYear
Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer.
    Journal of clinical pharmacology, 2016, Volume: 56, Issue:4

    Topics: Adult; Aged; Area Under Curve; Cisplatin; Etoposide; Female; Genotype; Glucuronosyltransferase; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Middle Aged; Neoplasms; Polymorphism, Single Nucleotide; Sulfonamides

2016
Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.
    Anti-cancer drugs, 2018, Volume: 29, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Glucuronosyltransferase; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Sulfonamides; Treatment Outcome

2018

Other Studies

1 other study(ies) available for etoposide and belinostat

ArticleYear
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer.
    Cell cycle (Georgetown, Tex.), 2011, Sep-15, Volume: 10, Issue:18

    Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Depsipeptides; DNA Breaks, Double-Stranded; Drug Synergism; Etoposide; Flow Cytometry; Fluorescent Antibody Technique; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Models, Theoretical; Phosphorylation; Small Cell Lung Carcinoma; Sulfonamides; Time Factors

2011